Purpose: To evaluate the immediate postoperative and midterm outcomes of complex thoracoabdominal aortic aneurysm (TAAA) treatment with fenestrated/branched physician-modified endovascular grafts (PMEGs) or open debranching of the visceral aorta with bypass graft revascularization plus endovascular aneurysm exclusion (hybrid repair). Materials and Methods: A retrospective analysis was conducted of 88 patients (mean age 70.0±10.6 years; 73 men) with complex TAAAs who underwent treatment with PMEGs (60, 68%) or a hybrid technique (28, 32%) between 2016 and 2019. The mean aneurysm diameter was 64.5±11.7 mm, and 37 patients (42%) were symptomatic. The Zenith TX2 and Ankura were the main stent-grafts used in the PMEG group. The hybrid technique involved visceral debranching with extra-anatomical bypass graft revascularization and subsequent stent-graft deployment (1- or 2-stage procedure). Results: In the PMEG group, 35 patients received modified stent-grafts with 4 fenestrations, 8 patients had 4 branches per device, and 17 patients had combinations (50 fenestrations and 18 branches) that successfully revascularized 228 of the 240 targets (95%). In the 28 hybrid cases, all 110 target vessels were successfully revascularized with bypass grafts. The overall 30-day mortality was 3.4% (2 PMEG and 1 hybrid), and the early rate of target vessel stenosis/occlusion was 3.3% (5 in PMEG group and 6 in the hybrid repair group). The 30-day morbidity was mainly attributed to pulmonary complications (15%), lower limb ischemia (8%), or spinal cord ischemia with paraplegia (6%). Eleven patients (13%) had deteriorated renal function with a >30% decrease in the glomerular filtration rate. The mean follow-up was 22.3±4.9 months, and mortality was 4.5% (3.3% in the PMEG group vs 7.1% in the hybrid repair group). Conclusion: PMEGs and hybrid techniques seem to be feasible treatment options for aortic aneurysms necessitating visceral vessel revascularization. PMEGs may have a lower morbidity than the hybrid technique, which nonetheless remains an important option available for complex aortic aneurysms.
4 April 2019 in Journal of Biomaterials Science, Polymer Edition
Bioresorbable vascular scaffolds are expected to replace the traditional metal stent, avoiding the long-term complications of metal stents. However, it is hard for the traditional scaffold manufacturing process to meet the requirements of individualized treatment for vascular lesions, which requires different morphologies. Here, we used a new method of scaffold manufacturing, three-dimensional printing technology, to prepare bioresorbable vascular scaffolds. The fabricated scaffold was loaded with sirolimus mixed with scaffold preparation material for slow drug release. The engineered, drug- loaded, bioresorbable vascular scaffold (BVS) was analyzed and tested in vivo. The scaffolds produced by three-dimensional printing technology exhibited good mechanical properties and in vitro degradation performance. The results also suggested that these scaffolds could maintain effective radial strength after long-term degradation and sustained release of the drug. As a new scaffold preparation method, it may provide a promising idea for developing bioresorbable vascular scaffold technology.
11 February 2025 in The Annals of Thoracic Surgery
Background: Delirium is a common complication in patients receiving extracorporeal membrane oxygenation (ECMO), but its prevalence and determinants remain uncertain due to variable clinical practices. We conducted a systematic review and meta-analysis to estimate the pooled prevalence of delirium in ECMO-supported patients, evaluate the influence of diagnostic tools and ECMO modality, and synthesize evidence on associated risk factors and outcomes. Methods: We systematically searched PubMed, Embase, and Web of Science up to May 2025 for studies reporting delirium prevalence in adult ECMO patients. Subgroup analyses were stratified by ECMO modality and delirium assessment tool. Meta-regression was performed to explore potential moderators. Publication bias was assessed visually using funnel plots and statistically using Egger’s and Begg’s tests via the metabias command. Results: Thirteen studies involving 8679 adult ECMO patients were included. The pooled prevalence of delirium was 40.54% (95% CI: 23.01–58.06%), with substantial heterogeneity (I2 = 98%; τ2 = 0.29; p < 0.01). Subgroup prevalence was 56.83% (95% CI: 41.52–72.14%) for VA-ECMO, 32.84% (95% CI: 3.39–62.29%) for VV-ECMO, and 37.24% (95% CI: 13.71–60.77%) for mixed cohorts; differences were not statistically significant. Delirium prevalence varied by assessment tools, ranging from 57% with NuDESC to 7% with ICD-10 coding. Meta-regression showed a negative but non-significant association between sample size and delirium prevalence (β = −0.000049; p = 0.088). Sensitivity analyses confirmed the robustness of pooled estimates. Conclusions: Delirium affects a substantial proportion of ECMO-supported patients and is linked to considerable clinical and neurocognitive morbidity. The marked heterogeneity in prevalence reflects differences in diagnostic tools and clinical management practices, including sedation strategies. These findings underscore the urgent need for standardized, ECMO-specific delirium assessment protocols and proactive prevention strategies. Well-designed prospective studies with uniform methodologies and long-term follow-up are essential to clarify the trajectory and impact of delirium in this high-risk population.
24 April 2026 in European Journal of Internal Medicine
Objectives: Thoracic aortic aneurysm (TAA) involving the aortic arch poses a significant risk of cerebrovascular accidents and presents technical challenges for repair. This report presents a hybrid approach combining carotid-subclavian bypass (CSbp) and physician-modified endografts (PMEGs) for a patient with extensive aortic arch involvement. Method: A 77-year-old asymptomatic man with a large TAA extending into the aortic arch underwent a hybrid procedure. The intervention included a CSbp and the deployment of a double-fenestrated PMEG, prepared using a Valiant Captivia stent-graft platform, with additional branches to accommodate supra-aortic vessels. Results: The patient’s intraoperative and postoperative course was uneventful, with no neurological or vascular complications. Follow-up CTA at 1 year showed a patent carotid-subclavian bypass, well-positioned stent grafts, and no evidence of endoleak or graft migration. Conclusion: The combination of carotid-subclavian bypass and PMEGs offers a feasible and effective treatment for complex TAA involving the aortic arch, particularly in high-risk patients unsuitable for open repair or total endovascular approaches.